Search results
Results From The WOW.Com Content Network
Despite operating for nearly two decades without profit, 23andMe went public in 2021 and reached a $6 billion valuation. The company's stocks were priced at $11.13 a share, but they've fallen ...
DNA-testing service 23andMe is making substantial efforts to nurse its feeble genetic core back to health. The company will lay off 40% of its workforce, over 200 employees, and cull its therapy ...
Another problem popped up in 2013, one that could have closed 23andMe for good. The Food and Drug Administration decided that 23andMe’s test and health reports about a person’s predisposition ...
With a $999 price-tag, it’s leaps and bounds more expensive than the next highest-priced tier you can buy. The service starts at $999 for a full year, and renews at $499. The service starts at ...
The financial struggles of genetic testing and ancestry company 23andMe are raising questions about the security of customers' DNA and other data. On Tuesday, 23andMe released its latest earnings ...
Once millions used it to find out about their family histories - this week it was almost delisted. What went wrong?
23andMe's once rising star has dimmed amid a series of setbacks, leading some users to wonder what will happen to their genetic data.
Genetic database builder 23andMe (NASDAQ: ME) stock slid 10% through 12:05 p.m. ET Tuesday. Curiously, though, the news that 23andMe reported today seemed generally of the "good" variety.